{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:45:14Z","timestamp":1792118714551,"version":"4.4.0"},"reference-count":149,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Neuropsychiatric disorders are multifaceted syndromes with confounding neurological explanations. It includes anxiety, depression, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia, Tourette\u2019s syndrome, delirium, dementia, vascular cognitive impairment, and apathy etc. Globally, these disorders occupy 15% of all diseases. As per the WHO, India has one of the largest populations of people with mental illnesses worldwide. The blood-brain barrier (BBB) makes it extremely difficult to distribute medicine to target cells in the brain tissues. However, it is possible through novel advancements in nanotechnology, molecular biology, and neurosciences. One such cutting-edge delivery method, nose-to-brain (N2B) drug delivery using nanoformulation (NF), overcomes traditional drug formulation and delivery limitations. Later offers more controlled drug release, better bioavailability, improved patient acceptance, reduced biological interference, and circumvention of BBB. When medicines are delivered via the intranasal (IN) route, they enter the nasal cavity and go to the brain via connections between the olfactory and trigeminal nerves and the nasal mucosa in N2B. Delivering phytochemical, bioactive and synthetic NF is being investigated with the N2B delivery strategy. The mucociliary clearance, enzyme degradation, and drug translocations by efflux mechanisms are significant issues associated with N2B delivery. This review article discusses the types of neuropsychiatric disorders and their treatment with plant-derived as well as synthetic drug-loaded NFs administered via the IN-delivery system. In conclusion, this review provided a comprehensive and critical overview of the IN applicability of plant-derived NFs for psychiatric disorders.<\/jats:p>","DOI":"10.3389\/fmed.2024.1463976","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:41:01Z","timestamp":1726720861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders"],"prefix":"10.3389","volume":"11","author":[{"given":"Anglina","family":"Kisku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambresh","family":"Nishad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Paliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Datusalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunjbihari","family":"Sulakhiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"239821281879927","DOI":"10.1177\/2398212818799271","article-title":"The genetics of neuropsychiatric disorders","volume":"2","author":"Bray","year":"2018","journal-title":"Brain Neurosci Adv"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-clinpsy-050817-084811","article-title":"Risk factors for depression: an autobiographical review","volume":"14","author":"Hammen","year":"2018","journal-title":"Annu Rev Clin Psychol"},{"key":"ref3","volume-title":"Mental health and COVID-19: early evidence of the pandemic\u2019s impact: scientific brief","year":"2022"},{"key":"ref4","article-title":"Coronavirus pandemic (COVID-19)","author":"Ritchie","year":"2020"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"110142","DOI":"10.1016\/j.pnpbp.2020.110142","article-title":"The effects of psychobiotics on the microbiota-gut-brain axis in early-life stress and neuropsychiatric disorders","volume":"105","author":"Tremblay","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ptr.2968","article-title":"Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders","volume":"24","author":"Kulkarni","year":"2010","journal-title":"Phytother Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.3390\/molecules26195905","article-title":"Controlled drug delivery systems: current status and future directions","volume":"26","author":"Adepu","year":"2021","journal-title":"Molecules"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.3390\/molecules25225294","article-title":"Nano carrier drug delivery systems for the treatment of neuropsychiatric disorders: advantages and limitations","volume":"25","author":"Zorkina","year":"2020","journal-title":"Molecules"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.4103\/1673-5374.241458","article-title":"Nose-to-brain drug delivery approach: a key to easily accessing the brain for the treatment of Alzheimer\u2019s disease","volume":"13","author":"Alexander","year":"2018","journal-title":"Neural Regen Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"G\u00e4nger","year":"2018","journal-title":"Pharmaceutics"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1016\/S0140-6736(16)30381-6","volume":"388","author":"Craske","year":"2016","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.psc.2009.06.002","article-title":"Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V","volume":"32","author":"Beesdo","year":"2009","journal-title":"Psychiatr Clin North Am"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1017\/S003329171200147X","article-title":"Global prevalence of anxiety disorders: a systematic review and meta-regression","volume":"43","author":"Baxter","year":"2013","journal-title":"Psychol Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.31887\/DCNS.2015.17.3\/dkupfer","article-title":"Anxiety and DSM-5","volume":"17","author":"Kupfer","year":"2022","journal-title":"Dialogues Clin Neurosci"},{"key":"ref15","article-title":"DSM-5 task force","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0974-8490.171100","article-title":"Effect of Beta vulgaris Linn. leaves extract on anxiety-and depressive-like behavior and oxidative stress in mice after acute restraint stress","volume":"8","author":"Sulakhiya","year":"2016","journal-title":"Pharmacognosy Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-981-32-9705-0_9","article-title":"The role of early life stress in HPA axis and anxiety","volume":"1191","author":"Juruena","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1542\/peds.2016-1758G","article-title":"Digital media, anxiety, and depression in children","volume":"140","author":"Hoge","year":"2017","journal-title":"Pediatrics"},{"key":"ref19","volume-title":"The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research","year":"1993"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1212\/CON.0000000000000607","article-title":"Diagnosis and management of anxiety disorders","volume":"24","author":"Giacobbe","year":"2018","journal-title":"Continuum"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.3928\/19382359-20190515-05","article-title":"Integrative approaches to stress, anxiety, and resilience","volume":"48","author":"Brown","year":"2019","journal-title":"Pediatr Ann"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.mcna.2017.06.005","article-title":"Anxiety and depression in cancer survivors","volume":"101","author":"Jean","year":"2017","journal-title":"Med Clin North Am"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/978-981-32-9705-0_28","article-title":"Anxiety disorders in the elderly","volume":"1191","author":"Andreescu","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11920-018-0923-x","article-title":"Moving to beat anxiety: epidemiology and therapeutic issues with physical activity for anxiety","volume":"20","author":"Kandola","year":"2018","journal-title":"Curr Psychiatry Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejphar.2014.09.049","article-title":"Honokiol abrogates lipopolysaccharide-induced depressive like behavior by impeding neuroinflammation and oxido-nitrosative stress in mice","volume":"744","author":"Sulakhiya","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"105259","DOI":"10.1016\/j.neuint.2021.105259","article-title":"Comprehending the potential of metallic, lipid, and polymer-based nanocarriers for treatment and management of depression","volume":"153","author":"Patel","year":"2022","journal-title":"Neurochem Int"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajp.2015.07.007","article-title":"Mechanisms linking depression co-morbid with obesity: an approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention","volume":"17","author":"Kurhe","year":"2015","journal-title":"Asian J Psychiatr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2020.19080848","article-title":"Hormonal treatments for major depressive disorder: state of the art","volume":"177","author":"Dwyer","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.31887\/DCNS.2019.21.4\/ebinder","article-title":"Epigenetics and depression","volume":"21","author":"Penner-Goeke","year":"2022","journal-title":"Dialogues Clin Neurosci"},{"key":"ref30","first-page":"620","article-title":"Depression and anxiety disorders: benefits of exercise, yoga, and meditation","volume":"99","author":"Saeed","year":"2019","journal-title":"Am Fam Physician"},{"key":"ref31","first-page":"321","article-title":"Chapter 21-genetics of autism spectrum disorder","volume-title":"Handbook of clinical neurology","author":"Ramaswami","year":""},{"key":"ref32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00787-012-0359-5","article-title":"Autism spectrum disorders","volume":"22","author":"Lauritsen","year":"2013","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1037\/0735-7028.34.1.26","article-title":"Advances in the diagnosis and treatment of autism spectrum disorders","volume":"34","author":"Kabot","year":"2003","journal-title":"Prof Psychol Res Pract"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2018.05.007","article-title":"Autism spectrum disorder: classification, diagnosis and therapy","volume":"190","author":"Sharma","year":"","journal-title":"Pharmacol Ther"},{"key":"ref35","first-page":"18","article-title":"Treatment of autism spectrum disorder in children and adolescents","volume":"46","author":"DeFilippis","year":"2016","journal-title":"Psychopharmacol Bull"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fnins.2018.00304","article-title":"Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder","volume":"12","author":"Eissa","year":"2018","journal-title":"Front Neurosci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJMra1917069","article-title":"Pharmacologic treatment of attention deficit-hyperactivity disorder","volume":"383","author":"Cortese","year":"2020","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/IOPN.IOPN_31_19","article-title":"Prevalence of attention-deficit hyperactivity disorder in India: a systematic review and meta-analysis","volume":"16","author":"Joseph","year":"2019","journal-title":"Indian J Psychiatr Nurs"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM199903113401007","article-title":"Treatment of attention-deficit-hyperactivity disorder","volume":"340","author":"Elia","year":"1999","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0006-3223(98)00240-6","article-title":"Neurobiology of attention-deficit hyperactivity disorder","volume":"44","author":"Faraone","year":"1998","journal-title":"Biol Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1176\/appi.ajp.159.1.36","article-title":"Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic","volume":"159","author":"Biederman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.biopsych.2004.10.020","article-title":"Attention-deficit\/hyperactivity disorder: a selective overview","volume":"57","author":"Biederman","year":"2005","journal-title":"Biol Psychiatry"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0193-953X(05)70039-3","article-title":"Attention-deficit hyperactivity disorder in adults","volume":"21","author":"Wender","year":"1998","journal-title":"Psychiatr Clin N Am"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"656921","DOI":"10.3389\/fnins.2021.656921","article-title":"Repurposing immunomodulatory imide drugs (IMiDs) in neuropsychiatric and neurodegenerative disorders","volume":"15","author":"Jung","year":"2021","journal-title":"Front Neurosci"},{"key":"ref45","article-title":"Mental disorder: World Health Organisation","year":"2022"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0165-0327(97)00160-2","article-title":"Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics","volume":"48","author":"Frye","year":"1998","journal-title":"J Affect Disord"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fnins.2018.00612","article-title":"Parkinson's disease: biomarkers, treatment, and risk factors","volume":"12","author":"Emamzadeh","year":"2018","journal-title":"Front Neurosci"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/ene.12883","article-title":"Disease-modifying treatments for multiple sclerosis-a review of approved medications","volume":"23","author":"Torkildsen","year":"2016","journal-title":"Eur J Neurol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.nurt.2008.01.008","article-title":"Symptomatic treatment of Huntington disease","volume":"5","author":"Adam","year":"2008","journal-title":"Neurotherapeutics"},{"key":"ref50","first-page":"176","article-title":"Therapies for human prion diseases","volume":"2","author":"Panegyres","year":"2013","journal-title":"Am J Neurodegener Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1056\/NEJMcp1007805","article-title":"Tourette\u2019s syndrome","volume":"363","author":"Kurlan","year":"2010","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"623684","DOI":"10.3389\/fpsyt.2021.623684","article-title":"Current limitations and candidate potential of 5-HT7 receptor antagonism in psychiatric pharmacotherapy","volume":"12","author":"Okubo","year":"2021","journal-title":"Front Psychiatry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-981-16-8146-2_14","article-title":"Containers based drug delivery for neuroscience","volume-title":"Micro-and nano-containers for smart applications","author":"Jose","year":"2022"},{"key":"ref54","first-page":"375","article-title":"Drug delivery strategies in multiple sclerosis, Huntington\u2019s disease and other neurodegenerative diseases","volume-title":"Drug delivery strategies in neurological disorders: challenges and opportunities","author":"Tarannum","year":"2024"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1080\/03602532.2020.1726942","article-title":"Lipid nanoformulations in the treatment of neuropsychiatric diseases: an approach to overcome the blood brain barrier","volume":"21","author":"Rehman","year":"2020","journal-title":"Curr Drug Metab"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/pharmaceutics15020678","article-title":"Nanosystems for brain targeting of antipsychotic drugs: an update on the most promising nanocarriers for increased bioavailability and therapeutic efficacy","volume":"15","author":"Ferreira","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.2174\/1381612828666220729104433","article-title":"Application of therapeutic nanoplatforms as a potential candidate for the treatment of CNS disorders: challenges and possibilities","volume":"28","author":"Sa","year":"2022","journal-title":"Curr Pharm Des"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/ASEC2022-13765","article-title":"The importance of nanosystems in antipsychotic drugs brain targeting","volume":"31","author":"Ferreira","year":"2022","journal-title":"Eng Proc"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/1566523220666200607185903","article-title":"Nanoparticle based gene therapy approach: a pioneering rebellion in the management of psychiatric disorders","volume":"20","author":"Rehman","year":"2020","journal-title":"Curr Gene Ther"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/bmj.g254","article-title":"Drug treatment of epilepsy in adults","volume":"348","author":"Schmidt","year":"2014","journal-title":"BMJ"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3390\/pharmaceutics12121230","article-title":"Intranasal nanoemulsions for direct nose-to-brain delivery of actives for cns disorders","volume":"12","author":"Bahadur","year":"2020","journal-title":"Pharmaceutics"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erd\u0151","year":"2018","journal-title":"Brain Res Bull"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.4088\/JCP.15f10026","article-title":"Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression","volume":"76","author":"Andrade","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.2147\/IJN.S41521","article-title":"Advanced drug delivery to the lymphatic system: lipid-based nanoformulations","volume":"8","author":"Khan","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/PAS.0b013e318285be00","article-title":"Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women","volume":"37","author":"Howitt","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","article-title":"Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis","volume":"295","author":"Costa","year":"2019","journal-title":"J Control Release"},{"key":"ref67","first-page":"497","article-title":"Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain: current development","volume":"11","author":"Wen","year":"2011","journal-title":"Discov Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"118635","DOI":"10.1016\/j.ijpharm.2019.118635","article-title":"Strategies to facilitate or block nose-to-brain drug delivery","volume":"570","author":"Martins","year":"2019","journal-title":"Int J Pharm"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"112999","DOI":"10.1016\/j.colsurfb.2022.112999","article-title":"Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases","volume":"221","author":"Teixeira","year":"2022","journal-title":"Colloids Surf B"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"9261","DOI":"10.48047\/AFJBS.6.5.2024.9261-9281","article-title":"Cerebro-spinal fluid (CSF) targeting through intra-nasal route by using nano-technology emerging as a powerful technique for different brain diseases","volume":"6","author":"Maurya","year":"2024","journal-title":"Afr J Biol Sci"},{"key":"ref71","first-page":"51","article-title":"Intranasal drug delivery system: a review","volume":"16","author":"Bava","year":"2024","journal-title":"J Adv Pharm Educ Res"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3724\/zdxbyxb-2023-0069","article-title":"Factors affecting nasal drug delivery and design strategies for intranasal drug delivery","volume":"52","author":"Hu","year":"2023","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1002\/ctd2.253","article-title":"Chances and challenges in intranasal administration delivery for brain disease treatment","volume":"3","author":"Zheng","year":"2023","journal-title":"Clin Trans Discovery"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4155\/tde-2023-0019","article-title":"Intranasal nanoparticulate delivery systems for neurodegenerative disorders: a review","volume":"14","author":"Babu","year":"2023","journal-title":"Ther Deliv"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.nlm.2014.07.006","article-title":"Intranasal dopamine treatment reinstates object-place memory in aged rats","volume":"114","author":"Trossbach","year":"2014","journal-title":"Neurobiol Learn Mem"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.3390\/pharmaceutics15112553","article-title":"Utility of a novel micro-spraying device for intranasal administration of drug solutions to mice","volume":"15","author":"Suzuki","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.2174\/138920112803341752","article-title":"Drug delivery systems from nose to brain","volume":"13","author":"Misra","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1515\/revneuro-2019-0063","article-title":"Therapeutic potential of intranasal photobiomodulation therapy for neurological and neuropsychiatric disorders: a narrative review","volume":"31","author":"Salehpour","year":"2020","journal-title":"Rev Neurosci"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"145921","DOI":"10.1016\/j.brainres.2018.08.024","article-title":"Intranasal administration of orexin peptides: mechanisms and therapeutic potential for age-related cognitive dysfunction","volume":"1731","author":"Calva","year":"2020","journal-title":"Brain Res"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.yebeh.2015.04.027","article-title":"Intranasal therapies for acute seizures","volume":"49","author":"K\u00e4lvi\u00e4inen","year":"2015","journal-title":"Epilepsy Behav"},{"key":"ref81","first-page":"439","article-title":"Non-invasive strategies for nose-to-brain drug delivery","volume":"10","author":"Trevino","year":"2020","journal-title":"J Clin Trials"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3390\/pharmaceutics14091974","article-title":"A review of non-invasive drug delivery through respiratory routes","volume":"14","author":"Zhang","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"179","DOI":"10.15171\/bi.2019.22","article-title":"Electrosprayed polymeric nanobeads and nanofibers of modafinil: preparation, characterization, and drug release studies","volume":"9","author":"Adibkia","year":"2019","journal-title":"Bioimpacts"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/gels8020097","article-title":"Modern herbal nanogels: formulation, delivery methods, and applications","volume":"8","author":"Sindhu","year":"2022","journal-title":"Gels"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnsyn.2020.00020","article-title":"Nanoliposomes as a therapeutic tool for Alzheimer\u2019s disease","volume":"12","author":"Ord\u00f3\u00f1ez-Guti\u00e9rrez","year":"2020","journal-title":"Front Synaptic Neurosci"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.2147\/DDDT.S177746","article-title":"Intranasal niosomes of nefopam with improved bioavailability: preparation, optimization, and in-vivo evaluation","volume":"12","author":"Abou-Taleb","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"061003","DOI":"10.1116\/6.0000380","article-title":"Design, characterization, and intracellular trafficking of biofunctionalized chitosan nanomicelles","volume":"15","author":"Li","year":"2020","journal-title":"Biointerphases"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"11728","DOI":"10.1007\/s11356-015-4370-5","article-title":"Effect of magnetic iron oxide (Fe3O4) nanoparticles on the growth and photosynthetic pigment content of Picochlorum sp.","volume":"22","author":"Hazeem","year":"2015","journal-title":"Environ Sci Pollut Res"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/1061186X.2019.1608553","article-title":"Brain targeting of resveratrol through intranasal lipid vesicles labelled with gold nanoparticles: in vivo evaluation and bioaccumulation investigation using computed tomography and histopathological examination","volume":"27","author":"Salem","year":"2019","journal-title":"J Drug Target"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2217\/nnm-2017-0270","article-title":"The inflammatory response to silver and titanium dioxide nanoparticles in the central nervous system","volume":"13","author":"Wu","year":"2017","journal-title":"Nanomedicine"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2019.03.002","article-title":"Progress in neuromodulation of the brain: a role for magnetic nanoparticles?","volume":"177","author":"Roet","year":"2019","journal-title":"Prog Neurobiol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.3390\/molecules25194489","article-title":"Dendrimers as modulators of brain cells","volume":"25","author":"Maysinger","year":"2020","journal-title":"Molecules"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.3390\/ijms25115842","article-title":"Nanoformulations in pharmaceutical and biomedical applications: green perspectives","volume":"25","author":"Petrovic","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-443-13205-6.00010-8","article-title":"Nanoformulations targeting Alzheimer\u2019s disease","volume-title":"Alzheimer\u2019s disease and advanced drug delivery strategies","author":"Kapoor","year":"2024"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.2174\/0113892010281459240118091137","article-title":"Naringenin Nanoformulations for neurodegenerative diseases","volume":"25","author":"Sahoo","year":"2024","journal-title":"Curr Pharm Biotechnol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22159\/ajpcr.2023.v16i10.48073","article-title":"Analytical methods for quality control of nanoformulations\u2014a review","volume":"16","author":"Reddy","year":"2023","journal-title":"Asian J Pharm Clin Res"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-323-91924-1.00011-3","article-title":"Protein and enzyme-based nanoformulations","volume-title":"Molecular pharmaceutics and nano drug delivery","author":"Kar","year":"2024"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"123","DOI":"10.54083\/PHA\/1.3.2023\/123-129","article-title":"Nano-bioformulation: a spanking new weapon for plant disease management","volume":"1","author":"Dutta","year":"2023","journal-title":"Plant Health Arch"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1079\/9781800623095.0006","article-title":"Nanoformulations of agrochemicals used to apply pesticides and fertilizers for crop improvement","volume-title":"Nanoformulations for sustainable agriculture and environmental risk mitigation","author":"Osman","year":"2023"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1201\/9781003305378_10","article-title":"Nanoformulation: a promising approach towards food fortification","volume-title":"Nanotechnology horizons in food process engineering","author":"Dhankhar","year":"2023"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1079\/9781800623095.0002","article-title":"Nanoformulation synthesis and mechanisms of interactions with biological systems","volume-title":"Nanoformulations for sustainable agriculture and environmental risk mitigation","author":"V\u00eelcoci","year":"2023"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2174\/0115672018270783231002115728","article-title":"Nanoformulations insights: a novel paradigm for antifungal therapies and future perspectives","volume":"21","author":"Ahuja","year":"2024","journal-title":"Curr Drug Deliv"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"6565396","DOI":"10.1155\/2020\/6565396","article-title":"Natural products and their bioactive compounds: neuroprotective potentials against neurodegenerative diseases","volume":"2020","author":"Mohd Sairazi","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.2174\/1381612824666180821165741","article-title":"Herbal and holistic solutions for neurodegenerative and depressive disorders: leads from ayurveda","volume":"24","author":"Sharma","year":"2018","journal-title":"Curr Pharm Des"},{"key":"ref105","article-title":"WHO establishes the global centre for traditional medicine in India","year":"2022"},{"key":"ref106","first-page":"266","article-title":"Indigenous herbal medicines used by tribal people in Satpuda Mountain Amarkantak, district Anuppur (MP)","volume":"5","author":"Malaiya","year":"2017","journal-title":"J Med Plants Stud"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"105013","DOI":"10.1016\/j.neuint.2021.105013","article-title":"Neuro-nutraceutical potential of Asparagus racemosus: a review","volume":"145","author":"Majumdar","year":"2021","journal-title":"Neurochem Int"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/medicines4020032","article-title":"Medicinal plants used for neuropsychiatric disorders treatment in the Hauts Bassins region of Burkina Faso","volume":"4","author":"Kinda","year":"2017","journal-title":"Medicines"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/plants10061238","article-title":"Innovative delivery systems loaded with plant bioactive ingredients: formulation approaches and applications","volume":"10","author":"Kyriakoudi","year":"2021","journal-title":"Plan Theory"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nano.2007.12.001","article-title":"Anxiety and cognitive effects of quercetin liposomes in rats","volume":"4","author":"Priprem","year":"2008","journal-title":"Nanomedicine"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neuropsychologia.2017.09.033","article-title":"Apathy in schizophrenia: a review of neuropsychological and neuroanatomical studies","volume":"118","author":"Bortolon","year":"2018","journal-title":"Neuropsychologia"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"107701","DOI":"10.1016\/j.yebeh.2020.107701","article-title":"Enlightening the neuroprotective effect of quercetin in epilepsy: from mechanism to therapeutic opportunities","volume":"115","author":"Akyuz","year":"2021","journal-title":"Epilepsy Behav"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijbiomac.2015.07.041","article-title":"Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder","volume":"81","author":"Bari","year":"2015","journal-title":"Int J Biol Macromol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/1574884714666190704115345","article-title":"Oral and intra-nasal administration of nanoparticles in the cerebral ischemia treatment in animal experiments: considering its advantages and disadvantages","volume":"15","author":"Alavian","year":"2020","journal-title":"Curr Clin Pharmacol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.2147\/IJN.S231480","article-title":"Innovative therapies and nanomedicine applications for the treatment of Alzheimer\u2019s disease: a state-of-the-art (2017\u20132020)","volume":"15","author":"Binda","year":"2020","journal-title":"Int J Nanomedicine"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3978\/j.issn.2305-5839.2015.12.04","article-title":"Niemann\u2013Pick disease treatment: a systematic review of clinical trials","volume":"3","author":"Santos-Lozano","year":"2015","journal-title":"Ann Transl Med"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/IJN.S151474","article-title":"Intranasal delivery of huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease","volume":"13","author":"Meng","year":"2018","journal-title":"Int J Nanomedicine"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/15701638113109990031","article-title":"Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting","volume":"10","author":"Ravouru","year":"2013","journal-title":"Curr Drug Discov Technol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"145385","DOI":"10.1016\/j.gene.2020.145385","article-title":"Deciphering the multi-scale mechanisms of Tephrosia purpurea against polycystic ovarian syndrome (PCOS) and its major psychiatric comorbidities: studies from network pharmacological perspective","volume":"773","author":"Choudhary","year":"2021","journal-title":"Gene"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1871524915666150624120516","article-title":"Synthetic and natural monoamine oxidase inhibitors as potential lead compounds for effective therapeutics","volume":"16","author":"Pathak","year":"2016","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3109\/21691401.2014.998824","article-title":"Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression","volume":"44","author":"Singh","year":"2016","journal-title":"Artificial cells, nanomedicine, and biotechnology"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1874104501004020001","article-title":"Novel therapeutic drugs for neuropsychiatric disorders","volume":"4","author":"Hashimoto","year":"2010","journal-title":"Open Med Chem J"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ogc.2018.05.002","article-title":"Treatment of peripartum bipolar disorder","volume":"45","author":"Clark","year":"2018","journal-title":"Obstet Gynecol Clin North Am"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"150","DOI":"10.34172\/apb.2021.016","article-title":"Development of carbamazepine nanostructured lipid carrier loaded thermosensitive gel for intranasal delivery","volume":"11","author":"Deshkar","year":"2021","journal-title":"Adv Pharm Bull"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/IJN.S15881","article-title":"Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model","volume":"6","author":"Eskandari","year":"2011","journal-title":"Int J Nanomedicine"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ejpb.2018.11.002","article-title":"Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents","volume":"133","author":"Musumeci","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"ref127","article-title":"Nanodiamond compositions and their use for drug delivery","volume-title":"Google Patents","author":"Roy","year":"2017"},{"key":"ref128","article-title":"Polyelectrolyte complexes for delivery of agents to the CNS","volume-title":"Google Patents","author":"Kabanov","year":"2019"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/pharmaceutics15030746","article-title":"Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery","volume":"15","author":"Maher","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4","article-title":"Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders","volume":"12","author":"Ressler","year":"2000","journal-title":"Depress Anxiety"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1517\/14728214.2015.1049996","article-title":"Emerging drugs for the treatment of anxiety","volume":"20","author":"Murrough","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref132","first-page":"389","article-title":"Pharmacological therapies for autism spectrum disorder: a review","volume":"40","author":"LeClerc","year":"2015","journal-title":"Pharm Ther"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/1381612822666151112151529","article-title":"Autism: pathophysiology and promising herbal remedies","volume":"22","author":"Bahmani","year":"2016","journal-title":"Curr Pharm Des"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3389\/fnhum.2015.00359","article-title":"Pathophysiology of ADHD and associated problems\u2014starting points for NF interventions?","volume":"9","author":"Albrecht","year":"2015","journal-title":"Front Hum Neurosci"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1055\/s-0040-1701658","article-title":"ADHD: current concepts and treatments in children and adolescents","volume":"51","author":"Drechsler","year":"2020","journal-title":"Neuropediatrics"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00002826-198306000-00002","article-title":"Pathophysiology of schizophrenia","volume":"6","author":"Stevens","year":"1983","journal-title":"Clin Neuropharmacol"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/pcn.12089","article-title":"Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia","volume":"68","author":"Altamura","year":"2014","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/S1353-8020(11)70027-X","article-title":"Parkinson\u2019s disease tremor: pathophysiology","volume":"18","author":"Hallett","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/s0387-7604(03)90002-7","article-title":"Pathophysiology of Tourette\u2019s syndrome: striatal pathways revisited","volume":"25","author":"Saka","year":"2003","journal-title":"Brain Dev"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/archpsyc.1993.01820130053009","article-title":"Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine","volume":"50","author":"Schweizer","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.nano.2006.12.001","article-title":"Antimicrobial effects of silver nanoparticles","volume":"3","author":"Kim","year":"2007","journal-title":"Nanomedicine"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev.me.41.020190.002253","article-title":"Serotonin-specific drugs for anxiety and depressive disorders","volume":"41","author":"Charney","year":"1990","journal-title":"Annu Rev Med"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"129","DOI":"10.9758\/cpn.2018.16.2.129","article-title":"The Wnt signaling pathway and related therapeutic drugs in autism spectrum disorder","volume":"16","author":"Bae","year":"2018","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"8119","DOI":"10.1073\/pnas.1705521114","article-title":"Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism","volume":"114","author":"Parker","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/anae.13407","article-title":"A comparison of intranasal dexmedetomidine for sedation in children administered either by atomiser or by drops","volume":"71","author":"Li","year":"2016","journal-title":"Anaesthesia"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"i102","DOI":"10.1007\/s00787-004-1010-x","article-title":"Non-stimulant medications in the treatment of ADHD","volume":"13","author":"Banaschewski","year":"2004","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.euroneuro.2009.02.005","article-title":"Intranasal application of dopamine reduces activity and improves attention in Naples high excitability rats that feature the mesocortical variant of ADHD","volume":"19","author":"Ruocco","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref148","first-page":"773","article-title":"Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD","volume":"30","author":"Jaffe","year":"1991","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.colsurfb.2012.05.010","article-title":"Phospholipid based colloidal poloxamer-nanocubic vesicles for brain targeting via the nasal route","volume":"100","author":"Salama","year":"2012","journal-title":"Colloids Surf B"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1463976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:41:08Z","timestamp":1726720868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1463976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":149,"alternative-id":["10.3389\/fmed.2024.1463976"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1463976","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"article-number":"1463976"}}